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Background. The endothelin (ET) receptors are subclassi-
fied into ETA, which are purely vasoconstrictive, and ETB. The
ETB receptors may cause either vasodilation by stimulating the
release of nitric oxide from endothelial cells, or vasoconstric-
tion of vascular smooth muscle cells (VSMC). The relative con-
tribution of ETA and ETB receptors to calcium signaling and
vasoconstriction in the renal microcirculation is not clear. Our
goal was to study the cytosolic calcium concentration ([Ca2+]i)
responses of fresh rat preglomerular VSMC and afferent arte-
rioles to agonists and antagonists of ETA and ETB receptors in
rats.
Methods. Fresh VSMC and afferent arterioles were isolated
using the magnetized microsphere/sieving technique, followed
by gentle collagenase digestion. [Ca2+]i was measured with fura-
2 ratiometric fluorescence.
Results. Afferent arterioles and VSMC responded to ET-1
stimulation with a rapid peak increase in [Ca2+]i ( = 287 ± 81
and 342 ± 55 nmol/L, respectively). The ETB receptor agonist
IRL 1620 stimulated a rise in [Ca2+]i in afferent arterioles (106±
35 nmol/L); subsequent addition of ET-1 at the IRL 1620 nadir
to stimulate ETA receptors caused a second peak that was twice
as large (213 ± 44 nmol/L). In VSMC, the ETB agonist peak in-
crease was 99 ± 12 nmol/L; addition of ET-1 then increased
[Ca2+]i by 294 ± 23 nmol/L. The ETB inhibitor BQ-788 pre-
vented stimulation of [Ca2+]i by IRL 1620 in afferent arterioles
and VSMC; subsequent stimulation of ETA receptors with ET-1
caused an increase in [Ca2+]i (239 ± 17 and 248 ± 22 nmol/L).
Pretreatment with the selective ETA inhibitor PD 156707 atten-
uated but did not abolish the responses to ET-1, suggesting that
the residual [Ca2+]i response was caused by ETB stimulation.
Conclusion. These results indicate that fresh preglomerular
VSMC as well as afferent arterioles have both ETA and ETB
receptors, and that the rapid peak [Ca2+]i responses to the ETB
agonist IRL 1620 are less than half that of subsequent stimula-
tion of ETA receptors with ET-1. The similarity of findings in
isolated VSMC and afferent arterioles suggests that responses
in VSMC in our arteriolar preparation overshadow any poten-
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tial contribution of endothelial cells when reagents are admin-
istered abluminally.
Endothelin-1 (ET-1) is considered to be one of the
most potent initiators of vascular contraction in mam-
mals [1]. The ET receptors are subclassified into ETA,
which are purely vasoconstrictive, and ETB, which may
cause either vasodilatation primarily by stimulating the
release of nitric oxide and sometimes prostacyclin from
endothelial cells, or vasoconstriction of VSMC [2]. ETA
is thought to be the predominant ET-1 subtype respon-
sible for vasoconstriction in VSMC of larger arteries; in
rats, ETB agonists failed to induce vasoconstriction in
pulmonary artery, carotid artery, or renal artery [3–5].
However, in small mesenteric arteries, ETB accounted
for about one half of the cytosolic calcium concentration
[Ca2+]i response to ET-1 [6].
While a number of laboratories have examined the ef-
fects of ET-1 in the renal microcirculation, neither the
differential effects of ET-1 on afferent and efferent arteri-
oles nor the relative contribution of ETA and ETB recep-
tors to calcium signaling and vasoconstriction have been
clearly delineated. For example, in the isolated perfused
hydronephrotic kidney preparation, direct visualiza-
tion of the microcirculation demonstrated greater ET-1
induced constriction of the afferent arteriole than the ef-
ferent arteriole [7]. In contrast to these findings, studies
in the split hydronephrotic kidney preparation revealed
that ET-1 and the specific ETB receptor agonist IRL 1620
constricted efferent arterioles two-fold more than affer-
ent arterioles [8, 9]. Studies of the responses to ET-1
in isolated afferent and efferent arterioles from nor-
mal rats demonstrated a small but significantly greater
concentration-dependent effect of ET-1 in efferent com-
pared with afferent arterioles [10].
Evidence for a role for ETB receptor–mediated vaso-
constriction in preglomerular arterioles largely has been
based upon studies of preparations in which the vascu-
lar effects of endothelins (ET-3 vs. ET-1), ETB agonists,
and pharmacologic inhibitors of ETA and ETB recep-
tors were measured. Changes in renal plasma flow and
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renal vascular resistance were measured after the admin-
istration of ET-1 and of ET-1 combined with the ETA
receptor antagonist BQ-123 [11]. Because BQ-123 did
not prevent the ET-1 mediated decrease in renal plasma
flow (although it did block systemic vasoconstriction),
this laboratory concluded that non-ETA receptor activ-
ity was responsible for the renal vascular effects [11].
Sarafotoxins have been employed to characterize the re-
ceptors mediating the effects of ET subtypes; the rank or-
der of potency was ET-1 = SX6b>ET-3SX6C [12]. In
studies of the systemic circulation and renal vasculature,
ET-1 and ET-3 and sarafotoxin 6b and 6c were found to
cause initial and transient depressor responses, followed
by dose-dependent increases in mean arterial pressure in
Sprague-Dawley (SD) rats with a rank order potency of
ET-1sarafotoxin 6c >ET-3 [13]. However, in the renal
circulation, these peptides caused equipotent falls in re-
nal blood flow. The fact that ETB receptors participated in
renal vasoconstriction was supported by the finding that
blockade of ETA receptors with BQ-123 was ineffective
in preventing renal vasoconstriction [13]. Thus, this lab-
oratory concluded that although systemic pressor effects
are mediated by both ETA and ETB receptors, the re-
nal vasoconstriction may be mediated predominantly by
ETB-like receptors. In another in vivo study, renal arterial
injection of sarafotoxin 6c, a specific ETB receptor ago-
nist, did not alter systemic blood pressure but maximally
decreased renal blood flow by 56% [14]. In contrast to
these studies, which implicate a vasoconstrictor role for
ETB in the renal microcirculation, studies of the renal
artery in rats failed to show contractile responses to ETB
agonist stimulation [5].
To our knowledge, only one laboratory has examined
the effect of ETA and ETB on calcium responses in fresh
preglomerular VSMC using the rank order potencies of
ET-1, -2, and -3 as an approach to discriminating between
the activation of ETA and ETB receptors; pharmacologic
agonists and inhibitors of the ETA or ETB receptors were
not employed [15]. These investigators concluded that
the [Ca2+]i responses were largely a consequence of ETA
receptor stimulation with little or no participation of ETB
receptors [15].
Taken together, the majority of previous studies in re-
nal microcirculation suggest that renal blood flow in the
rat is influenced by ETB receptors, and that both ETA
and ETB receptors may be present in preglomerular ar-
teries and arterioles, whereas ETB receptors are the ma-
jor subtype in efferent arteriolar VSMC [8, 9]. Given the
importance of arteriolar tone in controlling glomerular
hemodynamics, the relative contribution of ETA and ETB
mediated changes in [Ca2+]i and vasoconstriction in the
renal microcirculation is of critical consequence. Because
of the inconsistencies between blood flow studies and
experiments in isolated VSMC, we investigated calcium
signaling in both freshly isolated VSMC derived from pre-
glomerular vessels and in intact afferent arterioles of the
rat, utilizing ETA and ETB receptor agonists and antago-
nists. We studied both isolated fresh VSMC and afferent
arterioles in order to evaluate a potential contribution
of cell-to-cell crosstalk in VSMC and of interaction of
VSMC with endothelial cells. The specificity of the phar-
macologic probes we employed permitted assessment of
the relative roles of ETA and ETB receptors in stimulat-
ing an increase in intracellular calcium ([Ca2+]i), which
is an initiating signal for VSMC contraction.
METHODS
All studies were performed in compliance with the
guidelines and practices of the University of North
Carolina at Chapel Hill Institutional Animal Care and
Use Committee.
Preparation of fresh VSMC and afferent arterioles
We used the magnetized polystyrene microsphere-
sieving technique, as previously described, in our labo-
ratory [16–18] to isolate preglomerular vessels (<20 lm
in diameter) and individual VSMC from 6- to 7-week-old
SD rats maintained in the Chapel Hill Colony. Phosphate-
buffered saline (PBS), with the following composition in
mmol/L: 137 NaCl, 2.7 KCl, 0.88 KH2PO4, 6.4 Na2HPO4,
1.0 MgCl2, was adjusted to pH 7.4 at 4◦C and 25◦C and
pH 7.3 at 34◦C. The vessel segments in PBS containing
0.1% bovine serum albumin (BSA) were treated with
collagenase (type 1-A, 414 units/mg; Sigma Chemical Co.,
St. Louis, MO, USA) (0.005% to 0.01%) for 20 minutes at
34◦C to liberate individual VSMC. Collagenase type IV
(197 units/mg; Worthington, Lakewood, NJ, USA) was
employed for studies of intact afferent arterioles.
Arterioles and VSMC were loaded with fura-2-AM
(2 to 3 lmol/L) and 0.1% BSA for 45 to 60 minutes at 25◦
in the dark. After washing VSMC and arterioles twice
with PBS, Ca2+ (1.1 mmol/L) was added, and then the
suspension was kept on ice.
The concentrations of the agonists ET-1 and IRL 1620
were 10−7 mol/L, and those of the receptor inhibitors
BQ-788 and PD 156707 were 5 × 10−7 mol/L. VSMC
were preincubated with antagonists for one minute. The
concentrations of agonists and antagonists we chose were
based upon published results [2, 6, 12, 19, 20].
Measurement of cytosolic free calcium concentration
We measured cytosolic free calcium concentration
[Ca2+]i as previously described [17, 18, 21]. VSMC, iden-
tified morphologically by their spindle or crescent shape,
have been shown previously to contain smooth muscle
specific alpha-actin and heavy chain myosin SM-1 and
SM-2 [21]. Afferent arterioles were identified by their
morphology and measured diameters of 15 to 20 lm. As
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well, we required visualization of microspheres in the lu-
men in order to exclude the possibility that the vessel was
an efferent arteriole. The microspheres (4.0 to 4.5 lm) did
not pass beyond the glomerular capillaries. Cells and ar-
terioles were centered in a small window of the optical
field that was free of glomeruli or tubular fragments.
The VSMC were excited alternately with light of 340
and 380 nm wavelength from a dual-excitation wave-
length Delta-Scan equipped with dual monochronome-
ters and a chopper [Photon Technology International
(PTI), Lawrenceville, NJ, USA] as previously described
[16–18]. After passing signals through a barrier filter (510
nm), fluorescence was detected by a photomultiplier tube.
Signal intensity was acquired, stored, and processed by an
IBM-compatible Pentium computer and Felix software
(PTI). Background subtraction was performed in all stud-
ies. Generally there was a 1 to 2 second interruption in the
recording after the addition of reagents to the chamber.
A video camera projected images of VSMC and afferent
arterioles onto a video monitor, permitting visualization
of contraction of vessel segments and VSMC.
Reagents
We purchased collagenase type IA from Sigma, col-
lagenase type IV from Worthington, Fura-2-AM from
Molecular Probes (Eugene, OR, USA) or Teflab (Austin,
TX, USA); ET-1, BQ-788, and IRL-1620 from Califor-
nia Peptide Research (Napa, CA, USA); PD-156707
from Parke-Davis Pharmaceutical (Ann Arbor, MI,
USA), and magnetized microspheres from Spherotech
(Libertyville, IL, USA).
Statistics
The data are presented as mean ± SEM. In the com-
posite figures, SEM is shown every 20 seconds to give the
reader a sense of the variability of the data. Each data set
was derived from VSMC or afferent arterioles originating
from at least 3 separate experimental days, 2 rats (4 kid-
neys) per experiment. Individual cells or arterioles were
studied only once and then discarded. Paired data sets
were tested with Student paired t test. Multiple compar-
isons were analyzed using one-way analysis of variance
(ANOVA) for repeated measures followed by Student-
Neuman–Kuels post hoc test. P < 0.05 was considered
statistically significant.
RESULTS
Response to ET-1
A peak-plateau configuration characterized the [Ca2+]i
response of freshly isolated afferent arterioles to ET-1
(Fig. 1A and B). ET-1 almost immediately (<6 seconds)
increased [Ca2+]i from a baseline value of 73 ± 8 to a peak
of 360 ± 87 nmol/L (P < 0.01, N = 9). Similar results were
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Fig. 1. Cytosolic calcium response of afferent arterioles and arteriolar
vascular smooth muscle cells (VSMC) to endothelin-1 (ET-1). Overall
responses are shown as mean ± SEM. (A) Representative continuous
tracing of an afferent arteriole to ET-1. (B) Composite tracing of re-
sponse of afferent arterioles to ET-1. (C) Composite tracing of response
of fresh preglomerular VSMC to stimulation with ET-1.
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Fig. 2. Response of fresh afferent arterioles and arteriolar vascular
smooth muscle cells (VSMC) to the ETB receptor agonist IRL 1620.
(A) Afferent arterioles respond to IRL 1620 with a prompt peak. In
the continued presence of IRL 1620, subsequent addition of endothelin
(ET)-1 causes a second peak response. (B) In fresh VSMC, IRL 1620
stimulates a nearly immediate cytosolic calcium concentration ([Ca2+]i)
response, as does subsequent addition of ET-1 in the continued presence
of the ETB receptor agonist.
found in fresh individual VSMC; [Ca2+]i rose from 88 ±
17 to 430 ± 63 nmol/L after stimulation with ET-1 (N = 8,
P< 0.01) (Fig. 1C). The magnitude of the peak responses
to ET-1 in both preparations was not different (287 ± 81
vs. 342 ± 55 nmol/L, P > 0.5).
ETB agonist
To investigate the presence of functional ETB recep-
tors on preglomerular VSMC, we used the selective ETB
receptor agonist IRL 1620. Afferent arterioles responded
to IRL 1620 and to subsequent stimulation with ET-1 in
the continued presence of IRL 1620 (Fig. 2A). Baseline
[Ca2+]i rose from 119 ± 29 to 225 ± 48 nmol/L after stim-
ulation with the ETB agonist (N = 9, P < 0.01 for IRL
1620 vs. baseline); after addition of ET-1, [Ca2+]i further
increased from an ETB plateau value of 165 ± 40 to 378 ±
50 nmol/L (P < 0.01 for ET-1 vs. IRL 1620 nadir). The
peak response to IRL 1620 of 106 ± 35 nmol/L was
roughly one half that of the subsequent net peak response
to ET-1 of 213 ± 44 nmol/L, reflecting greater effects of
ETA stimulation. Comparing the peak [Ca2+]i response
to IRL 1620 (106 nmol/L) with that of ET-1 alone (287
nmol/L) (P < 0.05) is another line of evidence supporting
the premise that ETA is the more prevalent receptor in
afferent arteriolar VSMC.
Similar responses to ETB and ETA receptor stimula-
tion were recorded in fresh preglomerular VSMC. In-
dividual VSMC had a basal [Ca2+]i of 68 ± 10 nmol/L;
stimulation with IRL 1620 increased [Ca2+]i to 167 ± 13
(N = 9, P < 0.01). The subsequent increase in [Ca2+]i
from the IRL 1620 nadir of 132 ± 12 nmol/L to the peak
after the addition of ET-1 was 426 ± 47 nmol/L (P < 0.01
for ET-1 vs. IRL-1620 nadir). A comparison of the net
peak values for IRL 1620 versus ET-1 (99 ± 12 vs. 294 ±
23 nmol/L) shows that the peak IRL 1620 response in
VSMC was less than one half that of ET-1. Stimulation
of ETA receptors during ongoing occupation of ETB re-
ceptors with IRL 1620 in VSMC was similar to that of
afferent arterioles (P > 0.4).
ETB receptor inhibition
BQ-788 is a selective ETB receptor inhibitor [22].
When we pretreated afferent arterioles with this inhibitor
(N = 6), there was no stimulatory effect of IRL 1620 (Fig.
3A). Basal [Ca2+]i was 99 ± 16 nmol/L in the presence
of BQ-788, and was unchanged by the addition of this
ETB receptor agonist (104 ± 17 nmol/L). Subsequent ad-
dition of ET-1 caused a peak increase in [Ca2+]i of 239 ±
17 nmol/L (P < 0.01). The response to ET-1 was not dif-
ferent from that achieved by afferent arterioles that had
been first stimulated by an ETB receptor agonist and sub-
sequently exposed to ET-1 (213 ± 45 nmol/L, vide supra).
In similar experiments performed in fresh VSMC, base-
line [Ca2+]i in the presence of BQ-788 was 109 ± 17; after
addition of IRL 1620, [Ca2+]i was 117 ± 19 nmol/L (N
= 6). Stimulation with ET-1 resulted in a peak increase
in [Ca2+]i of 248 ± 22 nmol/L (P< 0.01 for ET-1 vs. BQ-
788) (Fig. 3B). There was not a statistically significant
difference in peak responses between this value, which
represents ETA stimulation during ETB receptor block-
ade, and that achieved by ETA receptor stimulation in
VSMC after activation of ETB receptors with IRL 1620.
ETA receptor inhibition
To further investigate the relationship between ETA
and ETB receptors in the renal microcirculation, we
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Fig. 3. Response of afferent arterioles and vascular smooth muscle
cells (VSMC) pretreated with the ETB receptor inhibitor BQ-788 to
subsequent addition of the ETB receptor agonist IRL 1620 and en-
dothelin (ET)-1. (A) In afferent arterioles, BQ-788 prevented a cytoso-
lic calcium concentration ([Ca2+]i) response to IRL 1620, but a typical
peak response to subsequent ET-1 addition was observed. (B) VSMC
did not respond to IRL 1620 in the continued presence of BQ-788, but
ET-1 stimulation then caused a prompt peak response.
employed the specific ETA inhibitor, PD 156707, which
had no effect on basal [Ca2+]i in either preparation. Af-
ter pretreatment of afferent arterioles or VSMC with this
ETA antagonist, a response to ET-1 should represent ac-
tivity of ETB receptors. Afferent arterioles pretreated
with PD 156707 responded to ET-1 with an increase in
[Ca2+]i from 74 ± 7 to 171 ± 23 nmol/L (N = 7, P < 0.01
for ET-1 compared with baseline) (Fig. 4A). This [Ca2+]i
increase of 97 ± 15 nmol/L was in the same range as that
noted earlier for the response of afferent arterioles to the
ETB agonist IRL 1620 (106 ± 35 nmol/L). Fresh VSMC
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Fig. 4. Response of afferent arterioles and vascular smooth muscle
cells (VSMC) pretreated with PD 156707 (ETA receptor inhibitor) to
endothelin (ET)-1. (A) Cytosolic calcium response of afferent arteri-
oles stimulated with ET-1. (B) In fresh VSMC, pretreatment with PD
156707 did not abolish the cytosolic calcium concentration ([Ca2+]i)
response to ET-1.
pretreated with PD 156707 responded to ET-1 with an in-
crease in [Ca2+]i of 113 ± 39 nmol/L (P < 0.01 compared
with baseline, N = 6) (Fig. 4B). Thus, in both afferent
arterioles and in isolated VSMC, the ETB agonist IRL
1620 alone, or ET-1 in the presence of the ETA inhibitor
PD 156707, stimulates similar increases in [Ca2+]i.
DISCUSSION
The aim of the present investigation was to analyze the
relative prevalence of ETA and ETB receptors in stim-
ulating an increase in [Ca2+]i in afferent arterioles and
in fresh VSMC derived from preglomerular microves-
sels. We used commonly accepted specific agonists and
inhibitors to dissect out the contribution of each subtype
of ET-1 rather than relying upon the less precise rank
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order potency of ET-1, -2, or –3, as has been done pre-
viously by others [15]. We found that ETB receptor ag-
onist IRL 1620 caused a prompt increase in [Ca2+]i in
both fresh VSMC and in afferent arterioles. Once the
plateau level of [Ca2+]i had been attained during contin-
ued ETB receptor activation, subsequent addition of ET-1
resulted in another sharp [Ca2+]i peak, suggesting the ad-
ditive effects of ETA receptor stimulation. Pretreatment
of VSMC or arterioles with the specific ETA receptor
inhibitor PD 156707 did not abolish the response to ET-
1, suggesting that the residual response was caused by
ETB receptor stimulation. These results imply that dur-
ing the very short time period of exposure to PD 156707,
there is not rapid desensitization between A and B re-
ceptors. Pretreatment of afferent arterioles and VSMC
with the specific ETB receptor inhibitor BQ-788 elimi-
nated the response to the selective ETB receptor ago-
nist IRL 1620; these cells then had a response to ET-
1 that was indistinguishable from arterioles and VSMC
that had first been stimulated with ETB agonists. Thus,
our results provide convincing evidence that both ETA
and ETB receptors stimulate an increase in [Ca2+]i in af-
ferent arteriolar VSMC independent of endothelial cells.
It is noteworthy that the sequence of receptor activation
had no impact on the results, demonstrating the inde-
pendence and additive nature of receptor activation in a
preparation of VSMC independent of endothelial cells.
The similarity of results in segments of afferent arteri-
oles and in individual VSMC suggests abluminal appli-
cation of ET-1 and pharmacologic agents act primarily
on VSMC with little or no participation of endothelial
cells.
Radioligand binding studies suggest that ETA and ETB
receptors are present in nearly equal proportions in rat
preglomerular vessels [23, 24]. In both of these studies,
renal microvessels were not denuded of endothelium be-
fore preparation for binding experiments. Hence, it is un-
clear to what extent endothelial ETB receptors contribute
quantitatively to the total amount of ETB receptor ex-
pression and binding in the renal microcirculation.
To delineate the possible role of ETB receptors in the
vasoconstrictor effect of ET-1 in the kidney, several labo-
ratories have employed various combinations of ETA and
ETB antagonists and ETB agonists. The results have been
mixed. In anesthetized rats, direct renal arterial admin-
istration of the ETB receptor agonist sarafotoxin 6c (in
doses that were subpressor for the systemic circulation)
decreased renal blood flow by more than 50%; injection
of subpressor doses of either ET-1 or of ET-3 (reported
to be representative of ETBETA) reduced renal blood
flow by about 80% [14]. In another study, doses of ET-1
were employed that increased mean arterial pressure as
well as decreased renal plasma flow [11]. When the ETA
receptor antagonist BQ-123 was infused with ET-1, the
increase in mean arterial pressure was abolished, but the
vasoconstrictor effect was unaffected, suggesting that a
receptor other than ETA was responsible for the renal
vasoconstriction [11].
In the split hydronephrotic rat kidney model, studies
with abluminal application of BQ-123, IRL 1620, and
BQ-788 suggested that preglomerular vasoconstriction
is mediated primarily by ETA receptors, whereas effer-
ent vasoconstriction is stimulated predominately by ETB
receptors [8]. In the more recent study of the split hy-
dronephrotic rat kidney, the local application of the ETB
receptor agonist IRL 1620 constricted both afferent and
efferent arterioles, with a more pronounced effect in the
efferent arteriole [9]. Taken together, these studies are
compatible with a vasoconstrictor role for both ETA and
ETB receptors on preglomerular microvessels, whereas
ETB receptors predominate on efferent arterioles.
Considerably less is known about the ability of ET-1
receptor subtypes to stimulate [Ca2+]i and about the re-
sponsible mechanisms. To examine the relative effects
of endothelin subtypes on rat fresh VSMC derived from
preglomerular microvessels by enzymatic digestion, the
activities of ET-1, -2, and -3 were compared [15]. The
relative potencies for the ETA receptor is ET-1 ≥ ET-2
ET-3, whereas for ETB receptor, ET-1 = ET-2 = ET-
3. Because of these relative rank-order potencies, these
authors felt that they could distinguish between activa-
tion of ETA and ETB receptors, and concluded that the
[Ca2+]i responses were largely a consequence of ETA re-
ceptor activation. Endothelin-3 caused only a trivial in-
crease in [Ca2+]i compared to ET-1 and 2. Interestingly,
they found an unusual delay of ∼56 seconds after expo-
sure of renal VSMC to ET-1, -2, and -3 before there was
a rise in [Ca2+]i [15]. In contrast, we generally observed
a nearly immediate increase (2 to 5 seconds) in [Ca2+]i in
response to ET-1 activation of fresh renal VSMC and af-
ferent arterioles. A number of studies in nonrenal vascu-
lar beds (pulmonary, mesenteric, carotid, spiral modiolar
arteries) likewise demonstrates nearly immediate [Ca2+]i
responses to ET-1 [25–28].
Studies in nonrenal vessels demonstrate heterogeneity
with respect to the presence of ETA and EB receptors in
different vascular regions. There was no evidence for a
vasoconstrictive effect of ETB receptors in carotid artery
of rats [4]. Likewise, there was no evidence for ETB recep-
tors in rat pulmonary artery because sarafotoxin 6c failed
to induce vasoconstriction [3]. In enzymatically dispersed
VSMC from rat renal artery, the ETB antagonist BQ-788
failed to affect the action of ET-1 in voltage-clamp exper-
iments [29].
Renal artery contractile responses to ETB receptor
stimulation were absent in 12- to 16-week-old Wistar
Kyoto (WKY) rats, but were present in age-matched
spontaneously hypertensive rats (SHR) [5]. Interestingly,
another group found evidence for ETB receptors on cul-
tured aortic VSMC of SHR and WKY, but not SD [30].
1816 Fellner and Arendshorst: ETA and ETB receptors on preglomerular VSMC
Cytosolic calcium measurements in small mesenteric ar-
teries of WKY showed a peak response to ET-1 (10−5
mol/L) of∼240 nmol/L and to sarafotoxin 6c (10−8 mol/L)
of∼120 nmol/L, suggesting that ETB receptors accounted
for about one half of the ET-1 response in this vascular
bed [6]. It would appear that large-caliber conduit ves-
sels are constricted primarily by ETA receptors, whereas
smaller diameter resistance vessels respond to both ETA
and ETB receptor activation of VSMC.
The fact that resistance rather than conduit vessels con-
tain ETB receptors suggests that redundancy of vascular
control systems is particularly important in those arteries
that control vascular tone. ETB vascular smooth muscle
receptors may actually be older in evolution than ETA
receptors. In the elasmobranch shark Squalus acanthias,
for example, the ventral aorta and anterior mesenteric
artery have only ETB receptors [31].
CONCLUSION
We have shown that in fresh preglomerular VSMC and
in afferent arterioles of SD rats, both ETA and ETB re-
ceptors stimulate a prompt increase in [Ca2+]i. Various
combinations of receptor agonists and antagonists reveal
consistent changes in [Ca2+]i that appear to be simply ad-
ditive, with ETA stimulation producing similar increases
if ETB receptors are blocked with an antagonist or are
activated with a receptor agonist. The relative density
and/or sensitivity of ETA receptors appear to be about
twice that of ETB receptors, assuming similar strength of
post-receptors second messenger systems. Future studies
are required to discover whether the calcium signaling
pathways for ETA and ETB receptors differ.
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